Berlin, Germany -- Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) announces that the Executive Board and Supervisory Board have resolved today to increase the share capital of the company against contribution in cash and without subscription rights. Epigenomics will place 2,671,088 new shares by way of a direct private placement with institutional investors in Europe. Epigenomics has received irrevocable commitments for the entire placement by a 100% subsidiary of BB MEDTECH AG (Schaffhausen, Switzerland) and funds managed by Abingworth LLP (London, UK)
